PARSIPPANY, N.J.–(EMWNews)–The Medicines Company (NASDAQ: MDCO) today announced that it has

acquired German-based Curacyte Discovery GmbH and its lead compound,

CU-2010, which is being developed for the prevention of surgical blood

loss.

CU-2010 is a small molecule serine protease inhibitor. In preclinical

studies, the compound has demonstrated a favorable pharmacokinetic

profile for the surgical setting with a rapid onset and offset of

effect, due to its short half life. The molecule was designed and is

being developed to address a significant unmet medical need that has

intensified for clinicians since the recent withdrawal of aprotinin. The

Medicines Company expects to commence Phase I clinical testing of

CU-2010 in 2008. This acquisition gives The Medicines Company an

integrated development capability around inhibitors of serine proteases –

a drug class that includes bivalirudin (Angiomax), the Company’s

leading hospital antithrombotic.

“The acquisition of CU-2010 fits within our

focused business development strategy—which is

to evaluate both early- and late-stage compounds in our core area of

expertise, critical care medicine, particularly thrombosis and

hemostasis,” stated Glenn Sblendorio,

Executive Vice President and Chief Financial Officer of The Medicines

Company. “CU-2010 brings further depth into

our existing portfolio of marketed and development products in cardiac

critical care.”

The Medicines Company continues to focus on advancing the treatment of

critical care patients through the delivery of innovative,

cost-effective medicines to the worldwide hospital marketplace.

“We are transitioning to a company with

multiple sources of revenue. Angiomax continues to grow in the United

States; we anticipate increased uptake in Europe in 2009 based on new

labeling and trials data; and with the approval of Cleviprex in the

U.S., we have strengthened our outlook considerably. We further

anticipate completion of worldwide Phase III trials of cangrelor in 2009

and the addition of CU-2010 and other compounds to the development

pipeline, provides more long term growth potential”

said Clive Meanwell, M.D., CEO. “We are also

pleased to demonstrate our commitment to investments in medical science

in Germany – one of the world’s

most innovative and important hospital critical care markets –

where Angiox and our other compounds can establish our presence strongly.”

Financial Impact of Transaction

The Medicines Company paid €14.5 million upon

signing of the agreement. On decision by The Medicines Company to

progress development of CU-2010 into Phase II, a further payment of €10.5

million will be made. If commercialized, a low, single-digit royalty and

a single future commercial milestone will be made.

The Medicines Company plans to announce third quarter 2008 financial

results in October. At that time, the Company will provide an update on

expected 2008 full-year expenses and net income based upon completion of

the valuation of the transaction and transition costs.

There will be a conference call with management Wednesday, August 6^th

at 8:00 a.m. Eastern Time to discuss the Curacyte Discovery acquisition

and its impact to ongoing operations. The conference call will be

available via phone and webcast. Dial in details are as follows –

domestic dial in 877-591-4949; international dial in 719-325-4869. The

webcast can be accessed at The Medicines Company website at www.themedicinescompany.com.

MDCO-G

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the

treatment of critical care patients through the delivery of innovative,

cost-effective medicines to the worldwide hospital marketplace. The

Company markets Angiomax^®

(bivalirudin) in the United States and other countries for use in

patients undergoing coronary angioplasty, as well as Cleviprex™

(clevidipine butyrate) injectable emulsion in the United States for

the reduction of blood pressure when oral therapy is not feasible or not

desirable. The Company also has one product, cangrelor, in late-stage

development. The Company’s website is www.themedicinescompany.com.

About Curacyte

Curacyte Discovery GmbH, is a wholly-owned subsidiary of Curacyte AG.

Curacyte AG is an advanced biopharmaceutical company dedicated to the

development of new therapeutics for acute and critical care conditions.

Curacyte’s lead product is hemoximer (Pyridoxalated

Hemoglobin Polyoxyethylene,

PHP). Hemoximer has been developed as a scavenger of nitric oxide, the

causative agent responsible for vasodilation and hypotension in shock.

The ability to scavenge and metabolize NO is one of the important

physiological functions of natural hemoglobin. Hemoximer has been

demonstrated to reverse the vasodilation and resolve the hypotension

associated with distributive shock. Hemoximer has completed Phase II

clinical development in its primary indication, distributive shock, and

is now entering a Phase III study in catecholamine-resistant

distributive shock. Apart from distributive shock, hemoximer is also

being studied as an adjunct to high-dose interleukin 2 (IL-2) cancer

therapy for patients with metastatic melanoma and renal cell carcinoma.

Shock is a frequent dose-limiting side effect of high-dose IL-2 therapy.

Hemoximer is the proposed International Non-Proprietary Name (INN) for

PHP. The Company’s website is www.curacyte.eu.

Statements contained in this press release about The Medicines Company

that are not purely historical, and all other statements that are not

purely historical, may be deemed to be forward-looking statements for

purposes of the safe harbor provisions under The Private Securities

Litigation Reform Act of 1995. Without limiting the foregoing, the words

“believes,” “anticipates” and “expects” and similar expressions are

intended to identify forward-looking statements. These forward-looking

statements involve known and unknown risks and uncertainties that may

cause the Company’s actual results, levels of activity, performance or

achievements to be materially different from those expressed or implied

by these forward-looking statements. Important factors that may cause or

contribute to such differences include whether the Company will have any

difficulties integrating its newly acquired businesses or products,

whether results obtained in preclinical studies will be indicative of

results obtained in clinical studies, whether the Company’s products

will advance in the clinical trials process on a timely basis or at all,

whether clinical trial results will warrant submission of applications

for regulatory approval, whether the Company will be able to obtain

regulatory approvals, whether physicians, patients and other key

decision-makers will accept clinical trial results, and such other

factors as are set forth in the risk factors detailed from time to time

in the Company’s periodic reports and registration statements filed with

the Securities and Exchange Commission including, without limitation,

the risk factors detailed in the Company’s Quarterly Report on Form 10-Q

filed on May 12, 2008, which are incorporated herein by reference. The

Company specifically disclaims any obligation to update these

forward-looking statements.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions